Chloroquine

Generic Name
Chloroquine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C18H26ClN3
CAS Number
54-05-7
Unique Ingredient Identifier
886U3H6UFF
Background

Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a number of other c...

Indication

Chloroquine is indicated to treat infections of P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also used to treat extraintestinal amebiasis.
...

Associated Conditions
Discoid Lupus Erythematosus (DLE), Extraintestinal Amebiasis, Malaria, Polymorphic Light Eruption (PLE), Porphyria Cutanea Tarda, Rheumatoid Arthritis, Sarcoidosis, Acute, uncomplicated Malaria
Associated Therapies
-

An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older

First Posted Date
2024-10-30
Last Posted Date
2024-12-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
300
Registration Number
NCT06666491
Locations
🇮🇳

GSK Investigational Site, Surat, India

Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi

First Posted Date
2023-10-16
Last Posted Date
2024-10-18
Lead Sponsor
Liverpool School of Tropical Medicine
Target Recruit Count
1000
Registration Number
NCT06083688
Locations
🇲🇼

Malaria Alert Centre, Blantyre, Malawi

The Seven Trial: Exploiting the Unfolded Protein Response

First Posted Date
2023-10-11
Last Posted Date
2023-10-11
Lead Sponsor
HonorHealth Research Institute
Target Recruit Count
12
Registration Number
NCT06076837
Locations
🇺🇸

Clinical Trials Nurse Navigator, Scottsdale, Arizona, United States

Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax

First Posted Date
2023-09-21
Last Posted Date
2023-09-22
Lead Sponsor
Dinka Dugassa
Target Recruit Count
100
Registration Number
NCT06044805
Locations
🇪🇹

Shecha Health Center, Arba Minch, South Ethiopia, Ethiopia

Comparing Chemoprevention Drugs for School-based Malaria Control

First Posted Date
2023-08-07
Last Posted Date
2023-08-07
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
646
Registration Number
NCT05980156
Locations
🇲🇼

Kamuzu University of Health Sciences, Blantyre, Malawi

TES of Chloroquine for Pv in the Philippines in 2016

First Posted Date
2023-07-25
Last Posted Date
2023-07-25
Lead Sponsor
Research Institute for Tropical Medicine, Philippines
Target Recruit Count
74
Registration Number
NCT05958797

Comparing Chemoprevention Approaches for School-based Malaria Control

First Posted Date
2022-02-17
Last Posted Date
2022-11-15
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
746
Registration Number
NCT05244954
Locations
🇲🇼

Kamuzu University of Health Sciences, Blantyre, Malawi

Southeast Asia Dose Optimization of Tafenoquine

First Posted Date
2021-01-12
Last Posted Date
2024-08-12
Lead Sponsor
University of Oxford
Target Recruit Count
700
Registration Number
NCT04704999
Locations
🇱🇦

Lao Oxford Mahosot Hospital Wellcome Trust Research Unit (LOMWRU), Vientiane, Lao People's Democratic Republic

🇻🇳

Oxford University Clinical Research Unit (OUCRU), Binh Phuoc, Vietnam

🇰🇭

Mahidol Oxford Tropical Medicine Research Unit (MORU), Cambodia, Siem Reap, Cambodia

and more 2 locations

Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2020-11-13
Last Posted Date
2021-10-07
Lead Sponsor
Fundacion Clinica Valle del Lili
Target Recruit Count
3217
Registration Number
NCT04627467
Locations
🇨🇴

Fundacion Valle del Lili, Cali, Valle Del Cauca, Colombia

Chloroquine Phosphate Prophylactic Use in Health Personnel Exposed to COVID-19 Patients

Phase 1
Conditions
Interventions
First Posted Date
2020-06-23
Last Posted Date
2020-07-14
Lead Sponsor
CMN "20 de Noviembre"
Target Recruit Count
200
Registration Number
NCT04443270
Locations
🇲🇽

Centro Médico Nacional "20 de Noviembre", Mexico City, Benito Juárez, Mexico

© Copyright 2024. All Rights Reserved by MedPath